Contrast Injectors Market

Bracco Imaging S.p.A., Bayer HealthCare, and Guerbet Group to Dominate the Global Contrast Injector Market

A number of key players are competing against each other in order to expand their existing customer base. In 2015, the contrast injector market was dominated by Bracco Imaging S.p.A (Italy), Bayer HealthCare (Germany), and Guerbet Group (France). Other players in this market include GE Healthcare (U.S.), Medtron AG (Germany), ulrich GmbH & Co. KG (Germany), AngioDynamics (U.S.) Sino Medical- Device Technology Co., Ltd. (China), Apollo RT Co., Ltd. (China), VIVID IMAGING (China), and Nemoto Kyorindo Co., Ltd. (Japan).

Bracco Imaging S.p.A is dominating the contrast injector market in 2016. The company is engaged in the discovery, development, manufacturing, and commercialization of imaging solutions for diagnostic imaging procedures to amplify the anatomic and functional visualization of internal body organs and areas. It also provides advanced administration systems for contrast imaging products. In 2011, the company acquired Swiss Medical Care (SMC) (Switzerland), to strengthen its automated system for contrast media injectors. Similarly, in 2008 and 2001, it acquired Acist Medical System (U.S.) and E-Z-EM Canada, Inc. (Canada) respectively. Bracco Imaging S.p.A serves customers in the Americas, Europe, and the Rest of the World with an employee base of 3,400 and a portfolio of 1,800 patients. The company’s notable revenue is from the European region followed by North America and RoW. The company maintains a direct sales force to reach out to its customers. It succeeded in creating a strong foothold in the market, owing to its diversified product portfolio, wide geographic reach, and focus on acquisitions and product launch.

Bayer HealthCare is second largest player in the contrast injector market in 2016. The company deals in R&D activities along with the manufacturing and marketing of products. Bayer HealthCare has two reporting segments, namely, Pharmaceuticals and Consumer Health. The Pharmaceuticals segment deals in prescription products specifically for women’s health and cardiology and specialty therapeutics in the areas of oncology, hematology, and ophthalmology. The Consumer Health segment has three divisions: consumer care, medical care, and animal health. The medical care division comprises two business units— diabetes care and radiology. The radiology business unit offers contrast-enhanced diagnostic imaging equipment along with the necessary contrast agents. The company continuously strives to strengthen its market position in various geographies by focusing on expansion and acquisitions for its contrast media injector products. The company acquired Medrad Inc., (U.S.) in 2011; the acquisition enabled Bayer AG to leverage its injector technology. In March 2014, the company invested around USD 132.9 million (EUR 100 million) to increase the production capacity of its plant in Beijing, China. This establishment enabled the company to meet the growing demand for its products by customers in China.

Guerbet Group is third largest player in the contrast injector market in 2016. The company is mainly focused on manufacturing and commercializing medical imaging contrast agents intended for diagnostic purposes. The company provides a wide range of contrast agents for X-ray examinations, MRI, and nuclear medicine. The company strives to strengthen its market position in various geographies by focusing on approval and acquisitions for its contrast injector products. For instance, the company acquired Mallinckrodt’s Contrast Media and Delivery Systems (CMDS) business for USD 270 million. The acquisition enabled Guerbert to serve new geographies like Australia and South Africa. The company also focuses on innovation and received awards for its contrast media injector products. For instance, in 2015, the company received an award from Red Dot Design for product design and New Product Innovation Award from Frost & Sullivan. Its wide range of product offerings, extensive geographic reach, and focus on innovation are contributing to the company’s large share in the market. The company has strong presence in EMEA (Europe, the Middle East, and Africa) countries followed by North America, APAC, and LATAM.

Other players operating in this market adopted the strategy of agreements, partnerships, and acquisitions, expansions, product launches, grants, product deployment, and approvals to increase their customer base across geographies and establish a strong foothold in the market.

Related Reports:

Contrast Injector Market by Product (Injector Systems (CT Injector, MRI Injector), Consumables (Injector Head, Tubing), Accessories), & Application (Radiology, Interventional Cardiology, Interventional Radiology) - Global Forecast to 2021

Mr. Rohan
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441

Report Code
MD 5244
Published ON
May, 2017
Choose License Type
Request Customization
Speak to Analyst
Speak to Analyst
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
  • What are the Known and Unknown Adjacencies Impacting the Contrast Injectors Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
© MarketsandMarkets Research Private Ltd. All rights reserved